Craif secured a $33 million Series D financing to support a US clinical trial of its urine-based pancreatic cancer assay. The Nagoya University spinout plans to scale its San Diego laboratory, pursue CLIA certification, and recruit about 500 higher-risk participants based on pancreatic anatomical abnormalities. The company said its miSignal Dx Pancreatic Cancer risk score is derived from microRNA extracted from urine exosomes and will run alongside its miSignal Scan multicancer early detection test. Craif also aims for a PMDA submission timeline by year-end or early next year, setting up a parallel regulatory track. Investors will likely focus on whether the clinical utility story can withstand scrutiny for screening or high-risk surveillance, a bar that has proved challenging for many early-detection assays.